Neuroblastoma Pipeline Insight

DelveInsight’s, “Neuroblastoma- Pipeline Insight, 2022,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Neuroblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

Global coverage

  • Neuroblastoma Understanding

Neuroblastoma: Overview

Neuroblastoma is a highly malignant tumor in infants. However, it may also occur in children under 5 years of age. Neuroblastoma is composed of neuroblasts, usually in the medulla of an adrenal gland. However, it is possible for the tumor to form in the nerve tissue of the spinal cord, chest, or neck. According to the National Cancer Institute, neuroblastoma is the first most common cancer in infants, and the third most common cancer in children. > 600 cases are diagnosed annually in the United States. It accounts for approximately 15% of all pediatric cancer fatalities. Incidence is higher in non-African-American children, and it is slightly more common in males than females. Neuroblastoma sometimes forms before birth and may be discovered during a fetal ultrasound. Usually, by the time of diagnosis, the cancer has metastasized, most commonly to the lymph nodes, bones, bone marrow, and liver. In infants, metastasis also occurs to the skin. Neuroblastoma may be caused by a gene mutation, passed from a parent to a child. When this occurs, the child is usually at a younger age, and more than one tumor forms in the adrenal glands. The most common symptoms are abdominal pain, discomfort, and a sense of fullness caused by an abdominal mass. Although neuroblastoma may be encountered initially as a mass on abdominal radiographs or US, confirmation of the diagnosis and definition of the exact extent of disease is obtained with either CT or MRI. NB shows a broad spectrum of clinical behaviour, as in some cases it may spontaneously regress or mature, whereas in others it may progress despite intensive multimodality treatment. Clinical outcome appears to correlate with a series of well-known clinical, histological and biological features, which can be used for risk-group stratification and treatment assignment according to current treatment protocols. Neuroblastoma is the most widespread solid tumor in childhood, presenting a plethora of symptoms and different responses to treatment. One of its features is the production of oxidative stress due to the accumulation of reactive species necessary for cancer metabolism, proliferation, and progression.

 

"Neuroblastoma- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuroblastoma pipeline landscape is provided which includes the disease overview and Neuroblastoma treatment guidelines. The assessment part of the report embraces, in depth Neuroblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neuroblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Neuroblastoma.

Neuroblastoma Emerging Drugs Chapters

This segment of the Neuroblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Neuroblastoma Emerging Drugs

 

67Cu MeCOSar Octreotate  : Clarity Pharmaceuticals

SARTATE™ is a next generation, highly targeted theranostic radiopharmaceutical with increased specificity and in-vivo stability, being developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2 (SSTR2). 67Cu SARTATE™ Peptide Receptor Radionuclide Therapy (PRRT) is being administered to Pediatric Patients with High-Risk Neuroblastoma (CL04). 7Cu SARTATE and 64Cu SARTATE™ have been granted FDA Orphan Drug Designation (ODD) status for the treatment and clinical management of neuroblastoma.

 

Isotretinoin : Nova Laboratories

13-CRA is one of several stereoisomers of retinoic acid, the main biologically active derivative of vitamin A, and has been used as a cancer chemopreventive agent due to its ability to induce cell differentiation, inhibit proliferation and induce apoptosis. 13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols. To overcome the challenge of dosing accuracy and palatability and to minimize the teratogenic risk for women of childbearing potential with the current method of manipulation of capsule, a convenient, ready-to-use, multi-dose, oral liquid formulation of 13-CRA has been developed.

 

AK 01 : Eli Lilly and Company

AurKa Pharma's asset, AK-01, has been shown to be highly selective for Aurora A, with potential clinical benefit observed in Phase 1 studies. Future studies will seek to determine if the selectivity profile of AK-01 can improve efficacy while limiting toxicity risks to a manageable level.

Further product details are provided in the report……..

Neuroblastoma: Therapeutic Assessment

This segment of the report provides insights about the different Neuroblastoma drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Neuroblastoma

There are approx. 35+ key companies which are developing the therapies for Neuroblastoma. The companies which have their Neuroblastoma drug candidates in the most advanced stage, i.e. Phase I/II, Clarity Pharmaceuticals.

 

Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Neuroblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuroblastoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuroblastoma therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuroblastoma drugs.

Neuroblastoma Report Insights

  • Neuroblastoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Neuroblastoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Neuroblastoma drugs?
  • How many Neuroblastoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuroblastoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neuroblastoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Neuroblastoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Neuroblastoma: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Neuroblastoma– DelveInsight’s Analytical Perspective

Late Stage Products (Pre Registration)

  • Comparative Analysis

Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

End Stage Products (Phase III)

  • Comparative Analysis

Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase I/ II)

  • Comparative Analysis

Isotretinoin : Nova Laboratories

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Neuroblastoma Key Companies

Neuroblastoma Key Products

Neuroblastoma- Unmet Needs

Neuroblastoma- Market Drivers and Barriers

Neuroblastoma- Future Perspectives and Conclusion

Neuroblastoma Analyst Views

Neuroblastoma Key Companies

Appendix

List of Table

Table 1: Total Products for Neuroblastoma

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Neuroblastoma

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Clarity Pharmaceuticals
• Y mAbs Therapeutics
• Nova Biopharma
• Eli Lilly and Company
• Illumina Radiopharmaceuticals
• Recombio
• United Therapeutics
• Molecular Insight Pharmaceuticals
• GE Healthcare
• Millennium Pharmaceuticals
• Genentech
• Actuate Therapeutics

 

Forward to Friend

Need A Quote